XEN-D0501
Type 2 Diabetes
Key Facts
About Pila Pharma
Pila Pharma is a Swedish public biotech advancing XEN-D0501, a novel oral TRPV1 antagonist, through clinical development for metabolic diseases. The company is strategically positioning its lead candidate as a differentiated, simple oral therapy for the massive obesity and type 2 diabetes markets, aiming to capture volume where injectable therapies may face limitations. With a completed rights issue fueling new obesity studies and a management team with Novo Nordisk heritage, Pila is progressing its clinical programs while actively engaging the investment community.
View full company profileAbout Pila Pharma
Pila Pharma is a Swedish public biotech advancing XEN-D0501, a novel oral TRPV1 antagonist, through clinical development for metabolic diseases. The company is strategically positioning its lead candidate as a differentiated, simple oral therapy for the massive obesity and type 2 diabetes markets, aiming to capture volume where injectable therapies may face limitations. With a completed rights issue fueling new obesity studies and a management team with Novo Nordisk heritage, Pila is progressing its clinical programs while actively engaging the investment community.
View full company profileAbout Pila Pharma
Pila Pharma is a Swedish public biotech advancing XEN-D0501, a novel oral TRPV1 antagonist, through clinical development for metabolic diseases. The company is strategically positioning its lead candidate as a differentiated, simple oral therapy for the massive obesity and type 2 diabetes markets, aiming to capture volume where injectable therapies may face limitations. With a completed rights issue fueling new obesity studies and a management team with Novo Nordisk heritage, Pila is progressing its clinical programs while actively engaging the investment community.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |